Budget 2026-27’s Duty Waiver on Cancer and Rare Disease Drugs Could Be Life-Saving for Millions

In its latest Union Budget for 2026-27, the Finance Ministry has unveiled a targeted intervention that could significantly ease the financial burden on patients battling cancer and rare diseases: a complete exemption of basic customs duty on 17 essential cancer drugs and duty relief for medicines used in the treatment of seven rare conditions.

Announced by Finance Minister Nirmala Sitharaman during her budget speech, the move is positioned as a patient-focused relief measure aimed at lowering the landed cost of imported therapies that are often prohibitively expensive for families and individuals. High-cost oncology medicines,  ranging from targeted therapies to advanced immunotherapies,  have historically attracted customs levies that artificially inflate retail prices, especially for treatments not manufactured domestically.

For rare disease sufferers, many of whom rely on personalised or niche medicines and specialised nutritional products not available in India, the duty exemption expands access to essential care and could be truly life-changing for patients who previously faced crippling costs.

Healthcare advocates have welcomed the step as a pragmatic effort to improve drug affordability, but experts caution that while duty relief narrows the cost gap, broader systemic reforms,  including insurance coverage and domestic drug production, remain critical to sustainably lowering treatment expenses across the care continuum.